Prozkoumejte nejčtenější články a videa na Campus Sanofi
Whelton PK, et al. Circulation. 2022.
Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity Albina Nowak et al., Mol Genet Metab. 2022 Sep-Oct;137(1-2):173-178.
Danish study finds more elderly and patients with comorbidities being diagnosed.